OC
ARRY

Oppenheimer & Co’s Array Biopharma Inc ARRY Stock Holding History

Oppenheimer & Co’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-45,400
Closed -$213K – 1512
2014
Q1 		$213K Hold
45,400
– – 0.01% 1210
2013
Q4 		$227K Buy
+45,400
New +$247K 0.01% 1151

Other funds holding ARRY

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Oppenheimer & Co's ARRY Position: Q2 2014 in Review

Oppenheimer & Co sold out of Array Biopharma Inc (ARRY) in Q2 2014, closing a stake of 45,400 shares — an estimated $213K sold.

Oppenheimer & Co first reported a position in ARRY in Q4 2013 and held it in 2 quarters. The position peaked at $227K in Q4 2013. 129 funds tracked by Wall St. Rank hold ARRY as of Q2 2014.

  • Oppenheimer & Co reported no remaining Array Biopharma Inc position as of Q2 2014 after selling out during the quarter.
  • Oppenheimer & Co sold 45,400 Array Biopharma Inc shares in Q2 2014, an estimated $213K.
  • Oppenheimer & Co first reported a position in Array Biopharma Inc in Q4 2013 and held it in 2 quarters.
  • Oppenheimer & Co's Array Biopharma Inc position peaked at $227K in Q4 2013.
  • 129 funds tracked by Wall St. Rank held Array Biopharma Inc as of Q2 2014.

Based on Oppenheimer & Co's 13F filing for Q2 2014, filed 14 Aug 2014.